{"id":48110,"date":"2022-09-08T15:01:49","date_gmt":"2022-09-08T13:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/"},"modified":"2022-09-08T15:01:49","modified_gmt":"2022-09-08T13:01:49","slug":"namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/","title":{"rendered":"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development"},"content":{"rendered":"
\n

TOLEDO, Ohio & TEL AVIV, Israel–(BUSINESS WIRE)–#CRO<\/a>—NAMSA<\/a>, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc<\/a>. (Nasdaq: NSPR), developer of the CGuard\u2122 Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization.\n<\/p>\n

<\/a><\/p>\n

\nInspireMD, which was founded in 2005 and became publicly traded in 2011, focuses on developing and commercializing the innovative CGuard\u2122 EPS stent platform and related delivery systems that provide sustained embolic and neurovascular protections. These products also include medical technologies for stroke prevention and carotid artery disease (CAD) treatments. With its proprietary MicroNet\u2122<\/a> technology, InspireMD is focused on changing the carotid and neurovascular market by working to make CGuard\u2122 EPS the standard of care in CAD while expanding its portfolio of solutions and pursuing applications of its MicroNet technology in other peripheral indications.\n<\/p>\n

\n\u201cWe are thrilled that InspireMD has selected NAMSA as their strategic outsourcing partner of choice,\u201d commented Dr. Christophe Berthoux, NAMSA CEO. \u201cNAMSA\u2019s mission is to deliver best-in-class global MedTech solutions through our people, expertise and technology and this collaboration is quintessential to this endeavor. With increasing demand to find trusted outsourcing partners to accelerate efficient clinical development of life-changing medical products, we are well positioned to work together in this joint venture. Leveraging NAMSA\u2019s full continuum of development services, combined with our deep-rooted cardiovascular and neurovascular expertise, we look forward to helping accelerate InspireMD\u2019s new product development efforts,\u201d Dr. Berthoux concluded.\n<\/p>\n

\nA key driver of success for MedTech Sponsors in the product development process is speed-to-market. Today, many companies are experiencing longer development timelines to accommodate an increasing number of clinical trials<\/a> for Class II and III products due to more complex regulatory<\/a> and clinical requirements. As a result, trial Sponsors are increasingly seeking strategic outsourcing partners such as NAMSA that have proven, trusted track records of decreasing development costs, providing multiple resource efficiencies, accelerating timelines and providing immediate access to therapeutic expertise<\/a> and knowledge.\n<\/p>\n

\n\u201cInspireMD has always sought ways to safely and efficiently accelerate product development through strategic outsourcing partners, and we have now found what we believe to be the ideal partner in NAMSA,\u201d commented Marvin Slosman, InspireMD CEO. \u201cWe look forward to establishing a more efficient path to market through NAMSA\u2019s expertise, experience and established relationships with regulatory authorities. With NAMSA\u2019s support, we can put more emphasis on integrating MicroNet\u2122 technology to develop products that are part of the new industry standard for sustained embolic\/neurovascular protections and stroke prevention. Our entire team looks forward to partnering with NAMSA as we continue to expand our presence globally and bring much-needed medical technology advancements to patients around the world,\u201d Slosman concluded.\n<\/p>\n

\nABOUT NAMSA<\/span><\/b>\n<\/p>\n

\nHelping medical device Sponsors improve healthcare since 1967, NAMSA is the world\u2019s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients\u2019 products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry\u2019s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com<\/a>\n<\/p>\n

\nAbout InspireMD, Inc.<\/span><\/b>\n<\/p>\n

\nInspireMD seeks to utilize its proprietary MicroNet\u00ae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD\u2019s common stock is quoted on the Nasdaq under the ticker symbol NSPR. Web: inspiremd.com<\/a>\n<\/p>\n

\nForward-looking Statements<\/span><\/b>\n<\/p>\n

\nThis press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d, \u201cscheduled\u201d or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company\u2019s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, including the changing regulatory environment in Europe and the timing of the renewal of certificate to continue to sell CGuard under the new MDR rule structure, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including the Company\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s web site at http:\/\/www.sec.gov<\/a>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nNAMSA Media Contact<\/span><\/b>
Leah Davidson, MA, MBA
\n
Sr. Manager, Global Marketing Communications
\n
Email: ldavidson@namsa.com<\/a>\n<\/p>\n

\nInspireMD Investor Contact
\n
<\/span><\/b>Craig Shore
\n
Chief Financial Officer
\n
InspireMD, Inc.
\n
Email: craigs@inspiremd.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOLEDO, Ohio & TEL AVIV, Israel–(BUSINESS WIRE)–#CRO—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard\u2122 Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48110","6":"format-standard","7":"category-industry"},"yoast_head":"\nNAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOLEDO, Ohio & TEL AVIV, Israel–(BUSINESS WIRE)–#CRO—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard\u2122 Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-08T13:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220908005151\/en\/667069\/21\/NamsaLogo-1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development\",\"datePublished\":\"2022-09-08T13:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/\"},\"wordCount\":1064,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005151\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/\",\"name\":\"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005151\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\",\"datePublished\":\"2022-09-08T13:01:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005151\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005151\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/","og_locale":"en_US","og_type":"article","og_title":"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development - Pharma Trend","og_description":"TOLEDO, Ohio & TEL AVIV, Israel–(BUSINESS WIRE)–#CRO—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard\u2122 Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-08T13:01:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220908005151\/en\/667069\/21\/NamsaLogo-1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development","datePublished":"2022-09-08T13:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/"},"wordCount":1064,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220908005151\/en\/667069\/21\/NamsaLogo-1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/","url":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/","name":"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220908005151\/en\/667069\/21\/NamsaLogo-1.jpg","datePublished":"2022-09-08T13:01:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220908005151\/en\/667069\/21\/NamsaLogo-1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220908005151\/en\/667069\/21\/NamsaLogo-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/namsa-and-inspiremd-announce-strategic-outsourcing-partnership-to-accelerate-new-product-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48110"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48110\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}